Q-Med gives notice to 50 of the co-workers in Uppsala

As part of the company’s work on focussing resources on the esthetics business, personnel reductions will be made at Q-Med’s facility in Uppsala.

As has been previously announced, Q-Med has decided to focus on the esthetics business. Sales and marketing of Hospital Healthcare products will be done via partners and there will be no further in-house development of new products within this area. This change leads to redundancies at Q-Med’s facility in Uppsala. Despite the fact that Q-Med assesses that some of these redundancies can be absorbed by the esthetics business, approximately 50 of the co-workers in Uppsala will need to leave the company.

Negotiations will be initiated with union representatives immediately.

Q-Med continues to have a positive view of the market for the company’s products. Furthermore, Q-Med assesses that the company will return to historical profitability levels within the Esthetics product area and that the Hospital Healthcare product area will display good profitability as a result of the above measures.


Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: + 46 (0)70 974 90 25
Alexander Kotsinas, Vice President and CFO
Tel: + 46 (0)73 500 11 11
Madelene Sandgren, Director Investor Relations and Corporate Communications,
Tel: + 46 (0)70 974 90 15

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.

Subscribe

Documents & Links